Abstract
Purpose
To evaluate diagnostic values of the liver imaging reporting and data system (LI-RADS) M (LR-M) category based on novel explicit criteria that accept both targetoid and nontargetoid LR-M features and the suggested reporting algorithm of LI-RADS v2018 to assess primary liver cancers (PLCs) on gadoxetic acid-enhanced MRI (Gd-EOB-MRI).
Methods
This retrospective study included 165 patients at high risk for hepatocellular carcinoma (HCC) with pathologically confirmed PLCs (HCC, n = 113; intrahepatic cholangiocarcinoma [iCCA], n = 23; and combined hepatocellular cholangiocarcinoma [cHCC-CCA], n = 29). Two radiologists independently analyzed Gd-EOB-MRI features and determined LI-RADS category for each tumor and categorized the likely etiology either as HCC or non-HCC malignancy if LR-M was assigned. Diagnostic performances for HCC or those for malignancy were compared according to imaging criteria.
Results
LR-M was assigned in 95.7%/91.3% of iCCAs; 55.2%/58.6% of cHCC-CCAs; and 21.2%/17.7% of HCCs in reviewers 1/2. Combination of LR-5 plus LR-M resulted in sensitivity of 95.2%/97.6% to diagnose PLCs as malignant, which were significantly higher than that of LR-5 plus “LR-M with ≥ 1 targetoid appearances” (84.8%/91.5%, Ps < 0.01). In comparison to LR-5, LR-5 plus “LR-M of HCC as likely etiology” resulted in significant increase in sensitivity (73.5%/79.6% versus 87.6%/92.9%, Ps < 0.001) but significant decrease in specificity (76.9%/75.0% versus 57.7%/50.0%, P = 0.002 and < 0.001) in the diagnosis of HCC.
Conclusion
The LR-M criteria v2018 are useful to differentiate non-HCC malignancies from HCCs and to accurately diagnose PLCs as a malignancy. Reporting the likely etiology in LR-M may facilitate a more sensitive detection of HCC, but along with a considerable decrease in specificity.
Similar content being viewed by others
Abbreviations
- APHE:
-
Arterial phase hyperenhancement
- cHCC-CCA:
-
Combined hepatocellular cholangiocarcinoma
- Gd-EOB-MRI:
-
Gadoxetic acid-enhanced magnetic resonance imaging
- HCC:
-
Hepatocellular carcinoma
- iCCA:
-
Intrahepatic cholangiocarcinoma
- LI-RADS:
-
Liver imaging reporting and data system
- LR-5:
-
LI-RADS category 5 (definitely HCC)
- LR-M:
-
LI-RADS category M (probably or definitely malignant, but not necessarily HCC)
- PLC:
-
Primary liver cancer
References
American College of Radiology. CT/MRI LI-RADS v2018 core. [https://www.acr.org/-/media/ACR/Files/RADS/LI-RADS/LI-RADS-2018-Core.pdf?la=en]
Tang A, Bashir MR, Corwin MT et al (2018) Evidence Supporting LI-RADS Major Features for CT- and MR Imaging-based Diagnosis of Hepatocellular Carcinoma: A Systematic Review. Radiology 286:29-48
Joo I, Kim H, Lee JM (2015) Cancer stem cells in primary liver cancers: pathological concepts and imaging findings. Korean J Radiol 16:50-68
Kim SA, Lee JM, Lee KB et al (2011) Intrahepatic mass-forming cholangiocarcinomas: enhancement patterns at multiphasic CT, with special emphasis on arterial enhancement pattern--correlation with clinicopathologic findings. Radiology 260:148-157
Jeon SK, Joo I, Lee DH et al (2019) Combined hepatocellular cholangiocarcinoma: LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging. Eur Radiol 29:373-382
Choi SH, Lee SS, Park SH et al (2019) LI-RADS Classification and Prognosis of Primary Liver Cancers at Gadoxetic Acid-enhanced MRI. Radiology 290:388-397
Ludwig DR, Fraum TJ, Cannella R et al (2019) Hepatocellular carcinoma (HCC) versus non-HCC: accuracy and reliability of Liver Imaging Reporting and Data System v2018. Abdom Radiol (NY) 44:2116-2132
Fowler KJ, Potretzke TA, Hope TA et al (2018) LI-RADS M (LR-M): definite or probable malignancy, not specific for hepatocellular carcinoma. Abdom Radiol (NY) 43:149-157
van der Pol CB, Lim CS, Sirlin CB et al (2019) Accuracy of the Liver Imaging Reporting and Data System in Computed Tomography and Magnetic Resonance Image Analysis of Hepatocellular Carcinoma or Overall Malignancy-A Systematic Review. Gastroenterology 156:976-986
American College of Radiology. CT/MRI LI-RADS v2018 manual.
Kim YY, Kim MJ, Kim EH et al (2019) Hepatocellular Carcinoma versus Other Hepatic Malignancy in Cirrhosis: Performance of LI-RADS Version 2018. Radiology 291:72-80
Joo I, Lee JM, Lee SM et al (2016) Diagnostic accuracy of liver imaging reporting and data system (LI-RADS) v2014 for intrahepatic mass-forming cholangiocarcinomas in patients with chronic liver disease on gadoxetic acid-enhanced MRI. J Magn Reson Imaging 44:1330-1338
Lee HS, Kim MJ, An C (2019) How to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI? Eur Radiol 29:2408-2416
Taouli B, Koh DM (2010) Diffusion-weighted MR imaging of the liver. Radiology 254:47-66
Funding
The authors received no specific funding for this work.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All authors declare that they have no conflict of interest.
Ethical approval
This retrospective study was approved by our institutional review board and the requirement for informed consent was waived.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Kim, M.Y., Joo, I., Kang, H.J. et al. LI-RADS M (LR-M) criteria and reporting algorithm of v2018: diagnostic values in the assessment of primary liver cancers on gadoxetic acid-enhanced MRI. Abdom Radiol 45, 2440–2448 (2020). https://doi.org/10.1007/s00261-020-02545-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00261-020-02545-z